[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"voiding-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:voiding-dysfunction":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,43,71,90,117,139,173,201],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100597202","association-between-qmaxegfr-ratio-and-luts-severity-in-men-over-40-100597202",false,"NCT07055425","Association Between Qmax\u002FeGFR Ratio and LUTS Severity in Men Over 40","The Role of Qmax\u002FeGFR Ratio in Assessing Symptom Severity and QoL in Men Over 40 With LUTS","Inclusion Criteria:\n\n* Male patients aged 40 years or older presenting with lower urinary tract symptoms (LUTS)\n* Able to provide informed consent\n* Willing and able to undergo uroflowmetry and blood testing\n* Able to complete the IPSS questionnaire, including the QoL item\n* Estimated glomerular filtration rate (eGFR) ≥ 30 mL\u002Fmin\u002F1.73m²\n\nExclusion Criteria:\n\n* History of urological surgery (e.g., prostatectomy, bladder surgery)\n* Diagnosed or suspected prostate cancer\n* Active urinary tract infection (based on clinical symptoms or urinalysis)\n* Neurological conditions affecting bladder function (e.g., Parkinson's disease, spinal cord injury)\n* Presence of an indwelling urinary catheter at enrollment\n* eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²\n* Inability to perform uroflowmetry or complete clinical evaluations","MALE","40 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","This study will look at how well a measure called the Qmax\u002FeGFR ratio is related to the severity of urination problems in men over the age of 40. Qmax is a test that shows how fast a person can urinate, and eGFR is a number that reflects kidney function. Men who have urinary symptoms will be asked to do a urine flow test, a blood test, and fill out a questionnaire about their symptoms and quality of life. We will study if there is a link between the Qmax\u002FeGFR ratio and how severe their symptoms are. The results may help doctors better understand how kidney and urinary function are related in men with these problems.",[24,25,26,27,28],"Lower Urinary Tract Symptom","Voiding Dysfunction","Male Urological Health","Renal Function","Benign Prostate Obstruction (BPO)",[24,28,26,25,30],"Aging Male","NOT_YET_RECRUITING","2025-08-30",{"date":34,"type":35},"2025-09-05","ACTUAL",{"date":37,"type":20},"2025-09-01",{"date":39,"type":20},"2026-05-01",{"name":41,"class":42},"Marmara University","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100594233","uroflowmetry-curve-types-and-ipss-in-men-with-luts-100594233","NCT07016776","Uroflowmetry Curve Types and IPSS in Men With LUTS","Evaluation of the Association Between Uroflowmetry Curve Patterns and IPSS Domains in Men With Lower Urinary Tract Symptoms","UROFLOW-IPSS","Inclusion Criteria:\n\n* Inclusion Criteria:\n* Male patients aged 40 years or older\n* Presenting with lower urinary tract symptoms (LUTS)\n* Able to complete the IPSS questionnaire\n* Underwent uroflowmetry and serum creatinine testing\n\nExclusion Criteria:\n\n* History of prior prostate surgery\n* Active urinary tract infection\n* Known diagnosis of neurogenic bladder\n* Current use of indwelling urinary catheter",{"count":52,"type":20},250,"This prospective observational study aims to evaluate the relationship between different uroflowmetry curve types and International Prostate Symptom Score (IPSS) domains in men presenting with lower urinary tract symptoms (LUTS). Participants will undergo routine clinical evaluations including uroflowmetry, laboratory assessments, and completion of the IPSS questionnaire.\n\nEach participant will be classified into one of five predefined uroflowmetry curve types (normal\u002Fbell-shaped, plateau, staccato, intermittent, or tower-like). The IPSS will be analyzed both as a total score and as two subdomains: storage and voiding symptoms. Additional data such as age, comorbidities, medication use, prostate volume, eGFR, and QoL score will also be recorded to assess potential correlations and predictive factors for symptom severity.\n\nThe goal of this study is to better understand how objective urodynamic findings correlate with patient-reported symptoms and to inform clinical decision-making in men with LUTS.",[55,56,25],"Lower Urinary Tract Symptoms (LUTS)","Benign Prostatic Hyperplasia (BPH)",[58,59,60,61,62],"International Prostate Symptom Score (IPSS)","Uroflowmetry","Flow curve pattern","Male urinary symptoms","Prospective observational study",{"date":64,"type":35},"2025-09-03",{"date":66,"type":20},"2025-09-15",{"date":68,"type":20},"2026-06-15",{"name":70,"class":42},"Tarik Emre Sener",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":85,"startDateStruct":86,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100596602","uroflowmetry-and-ipss-factors-influencing-surgical-decision-100596602","NCT07047599","Uroflowmetry and IPSS Factors Influencing Surgical Decision","Assessment of Clinical and Uroflowmetry Parameters as Predictors of Surgical Preference in Male Patients With Lower Urinary Tract Symptoms: A Prospective Observational Study","Inclusion Criteria:\n\n* Male patients aged 40 years and older\n* Presenting with lower urinary tract symptoms (LUTS)\n* Able to complete the IPSS questionnaire\n* Undergoing uroflowmetry as part of routine evaluation\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* History of urological surgery (e.g., TURP, HoLEP, radical prostatectomy)\n* Presence of known prostate or bladder cancer\n* Active urinary tract infection at the time of evaluation\n* Neurological conditions affecting voiding (e.g., Parkinson's disease, spinal cord injury)\n* Inability to perform uroflowmetry or incomplete IPSS data",{"count":19,"type":20},"This study aims to identify which symptoms or test findings lead men with lower urinary tract symptoms (LUTS) to consider surgical treatment. Male patients who visit the outpatient clinic for LUTS will be asked whether they would consider surgery in the future if their symptoms persist. Along with this, symptom severity scores (IPSS), quality of life scores, and uroflowmetry measurements such as maximum flow rate (Qmax) and post-void residual volume (PVR) will be collected. The goal is to determine which factors are most strongly associated with a desire for surgery. This is an observational, non-interventional study.",[24,28,25],[82,28,25,83,84],"Lower Urinary Tract Symptoms","IPSS","Urolfowmetry",{"date":34,"type":35},{"date":66,"type":20},{"date":88,"type":20},"2026-06-01",{"name":41,"class":42},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":96,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100598166","prevalence-of-functional-lower-urinary-tract-voiding-dysfunction-in-school-aged-children-100598166","NCT07067957","Prevalence of Functional Lower Urinary Tract Voiding Dysfunction in School-Aged Children","Inclusion Criteria:\n\n* Children aged 4-14 years old in our locality.\n\nExclusion Criteria:\n\n* Children with known anatomical anomalies of urinary tract\n* Children with known neurological anomalies (spinal dysraphism, multiple sclerosis, lumbar or spinal neuritis……… etc)\n* Children with history of back or lower urinary tract trauma\n* Parents who refuse participation","ALL","4 Years","14 Years",{"count":100,"type":20},500,"The aim of this study is to investigate the prevalence of voiding disorders and the related risk factors for the primary school-age children in El Ghrbia Government",[25,103,104,82,105,106],"Urinary Incontinence","Urination Disorders","Pediatrics","Constipation","2025-07-06",{"date":109,"type":35},"2025-07-16",{"date":111,"type":20},"2025-07-10",{"date":113,"type":20},"2025-11-30",{"name":115,"class":42},"Tanta University",1,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":96,"minAge":4,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":116},"100355886","treatment-outcomes-under-a-standardized-treatment-protocol-in-patients-suffered-substance-abuse-related-voiding-dysfunction-100355886","NCT03913819","Treatment Outcomes Under a Standardized Treatment Protocol in Patients Suffered Substance Abuse Related Voiding Dysfunction","Prospective Longitudinal Study on the Treatment Outcomes of Various Treatment Modalities Under a Standardized Treatment Protocol in Patients Suffered Substance Abuse Related Voiding Dysfunction","Inclusion Criteria:\n\n* Patients suffered substance abuse induced voiding dysfunction\n\nExclusion Criteria:\n\n* Patient not agreed for consent\n* Patient that will not comply to our treatment protocol",{"count":125,"type":20},1000,"With the increase of substance abuse over the world, substance abuse e.g. ketamine and methamphetamine related voiding dysfunction is becoming an important medical problem. However, while the clinical manifestation of the condition is becoming better defined, the underlying pathophysiology is still poorly understood. Moreover, majority of the current treatment is just based on the experience on some small case series and there is no treatment data for larger patient sample or standard recommended treatment in the literature. In order to improve the management of this condition, investigators have formulated a treatment protocol based on the current literatures on the management of voiding dysfunction and also a similar condition, interstitial cystitis \u002F painful-bladder syndrome (IC\u002FPBS). The protocol basically consists of the following modalities:\n\n* Basic information and education on the condition, principle of treatment and psychosocial support.\n* First line treatment will include a course of oral anti-inflammatory drugs (for the control of the inflammation process and pain) and anticholinergic agents (for the irritative urinary symptoms).\n* If these simple oral medication are found to be not effective, then further treatment will include other oral medications, such as amitriptyline and gabapentin, and some drugs that directly applied into the bladder cavity (hyaluronate) or bladder muscle (botulinum toxin).\n* For those patients with intractable symptoms and failed all the above treatments, surgical treatment (hydrodistension, augmentation cystoplasty) will be discussed.\n\nThe purpose of this research is to assess the effectiveness of the above treatment protocol in the management of substance induced voiding dysfunction and also assess any possible adverse events related to the usage of the drugs.",[25,128],"Substance Abuse","RECRUITING","2025-05-04",{"date":132,"type":35},"2025-05-06",{"date":134,"type":35},"2011-12-10",{"date":136,"type":20},"2026-12-31",{"name":138,"class":42},"Chinese University of Hong Kong",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":96,"minAge":147,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":151,"phases":152,"briefSummary":154,"conditions":155,"keywords":158,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":116},"100585989","home-pelvic-floor-improvement-trainer-trial-100585989","NCT06909539","HOme PElvic Floor Improvement Trainer Trial","Using a Perineometer Device With Gamification to Improve Symptom Outcomes in Pediatric Pelvic Floor Dysfunction","HoPE FIT","Inclusion Criteria:\n\n* Dysfunctional voiding symptoms without chronic pelvic pain.\n* Chronic pelvic pain with or without dysfunctional voiding symptoms.\n* Daytime enuresis, nocturnal enuresis, frequency, urgency, dysuria\n* 8 years - 18 years, no one under 8 and no one over 18.\n\nExclusion Criteria:\n\n\\- Has seen a physical therapist for traditional physical therapy of the pelvic floor due to urinary symptoms or chronic pelvic pain within the last 12 months.\n\nNote: This would include patients who begin physical therapy for their pelvic floor outside of the study while enrolled in the study.\n\n-All patients with the following conditions: severe developmental delay such as CP or wheelchair bound, cannot eat by mouth, mechanical ventilation dependence, etc.\n\n* Nonverbal or unable to effectively communicate needs and preferences.\n* Within the voiding dysfunction group, a diagnosis of a congenital GU anomaly (bladder exstrophy, cloacal anomaly, spina bifida, etc.)\n* No initial medication usage will be excluded; however, if the patient begins a new medication or treatment regimen during the study, the patient will be excluded.","8 Years","18 Years",{"count":150,"type":20},150,"INTERVENTIONAL",[153],"NA","This study will gauge the efficacy of a home biofeedback treatment device for pelvic floor dysfunction\u002Fvoiding dysfunction and pelvic pain. Investigators will test the utility of this device as a treatment alternative and\u002For temporary treatment for a patient's symptoms prior to or perhaps in lieu of their physical therapy appointment.",[156,157,25],"Pelvic Pain","Pelvic Floor Dysfunction",[159,160,161,162,163],"voiding dysfunction","pelvic floor dysfunction","pelvic pain","perineometer","gamification","2025-04-21",{"date":166,"type":35},"2025-04-24",{"date":168,"type":20},"2025-06-01",{"date":170,"type":20},"2027-01-01",{"name":172,"class":42},"University of Colorado, Denver",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":96,"minAge":180,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":151,"phases":184,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":116},"100561155","the-role-of-timed-awakening-in-treatment-of-enuresis-100561155","NCT06586476","The Role of Timed Awakening in Treatment of Enuresis","A Randomized Clinical Trial to Investigate the Efficacy and Feasibility of Timed Awakening in the Treatment of Enuresis","Inclusion Criteria:\n\n* Our inclusion criteria are new and recently evaluated (within past 6 months) patients who are English-speaking\n* aged 6-17\n* referred to the urology clinic for enuresis (Enuresis in our study is defined as nocturnal or diurnal enuresis (more than 1 bedwetting episode\u002Fweek) for greater than 3 months)\n\nExclusion Criteria:\n\n* Diagnosis of enuresis with comorbid diagnosis of diabetes mellitus (type 1 and 2), diabetes insipidus, chronic kidney disease, polyuria and\u002For polydipsia\n* Structural urologic disease (evaluated via baseline imaging)\n* Diagnosis of neurodevelopmental delays or conditions (i.e. celebral palsy, autism spectrum disorder) that hinders inability to follow age-appropriate instructions\n* Not potty trained\n* Improved or resolved enuresis for patients recently evaluated (within the past 6 months)\n* Non-English speaking\n* Patients currently on any over-active-bladder (OAB) medications (b3- agonists, antichloingerics) or alpha blockers for urinary symptoms (i.e. alfuzosin, tamsulosion, etc) or anti-diurectic medications for urinary symptoms (i.e.: desmopression (DDAVP))\n* Patients currently using bed-wetting alarms\n* Patients and families who are actively seeing Pediatric Clinical Urologic Psychologist.\n* Inability or unwillingness of individual or legal guardian\u002Frepresentative to give written informed consent or participate in the study","6 Years","17 Years",{"count":183,"type":20},40,[153],"The goal of this clinical trial is to evaluate the effectiveness of nightly timed awakening in the treatment of nocturnal enuresis in children aged 6-17. The main questions it aims to:\n\n* Determine feasibility of nightly timed awakenings\n* Determine the role, if any, of comorbidities on resolution of enuresis\n* Determine incidence of daytime accidents\n* Obtain patient and parental satisfaction scores\n\nResearchers will compare a control group to treatment groups to see if there is any impact on nocturnal enuresis.\n\nParticipants will be woken up by parents in the middle of the night to use the restroom. In addition, participants will receive 30 minute psychotherapy sessions using telehealth.",[187,25],"Nocturnal Enuresis",[189,190,191],"Lifting","Incontinence","Bedwetting","2024-09-05",{"date":194,"type":35},"2024-09-19",{"date":196,"type":20},"2024-10-01",{"date":198,"type":20},"2026-12-01",{"name":200,"class":42},"Children's Hospital Los Angeles",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":208,"minAge":148,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":151,"phases":211,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":116},"100473054","efficacy-of-alpha-blockers-tamsulosin-in-the-treatment-of-symptomatic-dysuria-in-multiple-sclerosis-in-women-100473054","NCT05439902","Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women","ALPHA-SEP","Inclusion Criteria:\n\n* The patient must have given their free and informed consent and signed the consent form\n* The patient must be a member or beneficiary of a health insurance plan\n* Patient with multiple sclerosis (EDSS score \\\u003C 7.5).\n* Moderate to severe dysuria (IPSS score \\> 7) due to bladder sphincter dyssynergia confirmed by complete urodynamic workup.\n* Patient under stable treatment.\n\nExclusion Criteria:\n\n* The subject is participating in another category 1 interventional study, or a trial involving a non-CE marked or CE marked off-label medical device or is in a period of exclusion determined by a previous study\n* The subject refuses to sign the consent\n* It is impossible to give the subject informed information\n* The patient is under safeguard of justice or state guardianship\n* Hypersensitivity to tamsulosin hydrochloride, including angioedema induced by the drug or any of the excipients.\n* History of orthostatic hypotension.\n* Severe hepatic impairment.\n* Concomitant treatment with diclofenac, warfarin, CYP3A4 inhibitors.\n* \\- Patient with complete urinary retention at the time of the pre-inclusion consultation, requiring management by intermittent self-catheterization or, failing that, an indwelling bladder catheter from the outset.\n* Major medical or psychiatric illness that, in the opinion of the investigator, would place the subject at risk or could compromise compliance with the study protocol.\n* Presence of another neurological pathology (excluding MS).\n* Swallowing problems that compromise oral medication.\n* Scheduled cataract surgery within 4 months.\n* Pregnant, parturient or breastfeeding patient.","FEMALE",{"count":210,"type":20},60,[153],"Multiple sclerosis (MS) is the leading non-traumatic cause of severe acquired disability in young people. The disease is defined by relapses, which can affect all neurological functions depending on the location of the new inflammatory lesion(s). The disease can thus manifest itself through bladder and bowel disorders (BWS), which affect approximately 80% of MS patients in all stages. Lower urinary tract dysfunction has a significant negative impact on the quality of life of patients and places a significant burden on the healthcare system in terms of resource allocation. In addition, there is a risk of long-term chronic renal failure, an infectious risk (recurrent cystitis and\u002For pyelonephritis, sometimes life-threatening) and a lithiasis risk.\n\nThe most frequently observed urinary symptoms are: urinary frequency, urgency with or without urinary incontinence, dysuria and chronic retention of urine. These disorders most often combine bladder hyperactivity and dysuria. This dysuria may be responsible for recurrent urinary tract infections, lithiasis, alteration of renal function.\n\nThe only therapeutic class currently used to treat dysuria in MS is alpha-blockers. Tamsulosin, alfusozin and doxazosin induce relaxation of the urethral smooth sphincter and prostatic urethral muscle fibers, facilitating the removal of subvesical obstruction and bladder emptying.\n\nThe study investigators hypothesize that treatment with tamsulosin 0.4 mg daily in adult MS patients with dysuria will result in symptom improvement as assessed by the International Prostate Symptom Score (IPSS) and Urinary Symptom Profile (USP) scores, a decrease in post-void residual, and an improvement in urine flow and quality of life.",[214,215,82,25,216],"Multiple Sclerosis","Dysuria","Urinary Retention","2024-06-24",{"date":219,"type":35},"2024-06-25",{"date":221,"type":35},"2022-10-05",{"date":223,"type":20},"2026-03",{"name":225,"class":42},"Centre Hospitalier Universitaire de Nīmes"]